A5102711737- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Bladder and Urothelial Cancer Treatments
- Organ Transplantation Techniques and Outcomes
- Urinary and Genital Oncology Studies
- Cancer, Lipids, and Metabolism
- Urological Disorders and Treatments
- Endometrial and Cervical Cancer Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Pediatric Urology and Nephrology Studies
- Liver physiology and pathology
- Bone and Joint Diseases
- Bone health and treatments
- Esophageal Cancer Research and Treatment
- Kidney Stones and Urolithiasis Treatments
- Organ Donation and Transplantation
- Spondyloarthritis Studies and Treatments
- Renal and Vascular Pathologies
- Rheumatoid Arthritis Research and Therapies
- Multiple Myeloma Research and Treatments
- Abdominal Trauma and Injuries
- Organ and Tissue Transplantation Research
Ghent University Hospital
2014-2025
Universitair Ziekenhuis Brussel
2024
Utrecht University
2018
University Medical Center Utrecht
2018
University Hospital of Zurich
2018
Emory University
2018
Centre for Cosmology and Particle Physics Phenomenology
2018
Bayer (France)
2017
Astellas Pharma (United Kingdom)
2017
AZ Maria Middelares
2017
Purpose Retrospective studies suggest that metastasis-directed therapy (MDT) for oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to assess the benefit of MDT in a randomized phase II trial. Patients and Methods In this multicenter, randomized, study, patients with asymptomatic PCa were eligible if they had biochemical recurrence after primary treatment curative intent, three or fewer extracranial metastatic lesions on choline positron emission...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co‐primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. STOMP and ORIOLE trial reports suggested metastasis-directed therapy (MDT) oligometastatic castration-sensitive...
10 Background: Multiple randomized phase II trials suggest that metastasis-directed therapy (MDT) for oligometastatic prostate cancer (PCa) improves progression-free survival, but the majority of lack longer follow-up. We present updated 5-year results from STOMP-trial. Methods: In this multicentre, randomised, study, asymptomatic PCa patients were eligible in case a biochemical recurrence following primary treatment with curative intent and presenting up to 3 extracranial on choline PET-CT...
Objectives To describe the anatomical patterns of prostate cancer ( PC a) recurrence after primary therapy and to investigate if patients with low‐volume disease have a better prognosis as compared their counterparts. Materials Methods Patients eligible for an 18‐F choline positron‐emission tomography PET )‐computed CT ) were enrolled in prospective cohort study. Eligible had asymptomatic biochemical treatment testosterone levels >50 ng/mL. The number lesions was counted per scan....
Radiotherapy to the prostate (RTp) prolongs survival for patients with low-volume, newly diagnosed metastatic cancer (ndmPC).to evaluate whether cytoreductive radical prostatectomy (cRP) is equally beneficial as RTp in low-volume ndmPC.A multicenter prospective registry was established 2014 observe ndmPC. Eligible were offered cRP or RTp. For this study we selected only ndmPC (n = 109). Of these, 48, 26, and 35 underwent cRP, RTp, no local therapy (NLT), respectively. Median follow-up 32 mo...
In metastatic castration-sensitive prostate cancer (mCSPC), disease volume plays an integral role in guiding treatment recommendations, including selection of docetaxel therapy, metastasis-directed and radiation to the prostate. Although there are multiple definitions volume, they have commonly been studied context metastases detected via conventional imaging (CIM). One such numeric definition termed oligometastasis, is heavily dependent on sensitivity modality. We performed international...
Prostate-specific membrane antigen (PSMA) is highly overexpressed in prostate cancer. Many PSMA analog radiotracers for PET/CT cancer staging have been developed, such as <sup>68</sup>Ga-PSMA-11. This radiotracer has achieved good results multiple clinical trials, but because of the superior imaging characteristics <sup>18</sup>F-fluoride, <sup>18</sup>F-PSMA-11 was developed. The aim this study to evaluate administration safety and radiation dosimetry <sup>18</sup>F-PSMA-11. <b>Methods:</b>...
•Synchronous metastatic CSPC is associated with lower AR activity than metachronous disease.•Patients synchronous derive a greater benefit to combination plus non AR-based therapy.•Clinical and biologic differences between metastasis are most prominent in low-volume disease. BackgroundMetastatic castration-sensitive prostate cancer (mCSPC) commonly classified into high- subgroups which have demonstrated differential biology, prognosis, response therapy. Timing of has similarly clinical...
Recently, a 18F-labeled derivative of the widely used 68Ga-PSMA-11 was developed for PET imaging prostate cancer. Although 18F-PSMA-11 has already been evaluated in Phase I and II clinical trial, preclinical evaluation this radiotracer is important further understanding its dynamic behavior. Saturation binding experiments were conducted by incubation LNCaP cells with or 1 h, followed determination specific aspecific binding. Mice bearing PC-3 xenografts each received ± 3.7 MBq acquisition...
Several scan parameters for PET imaging with 18F-PSMA-11 such as dosage, acquisition time and duration were evaluated to determine the most appropriate protocol, well effect of furosemide administration on lesion visualization. Forty-four patients randomly assigned a dosage group (2.0 ± 0.2 or 4.0 0.4 MBq/kg 18F-PSMA-11). All received full-body PET/CT 1 h 3 after radiotracer injection min/bed position. For comparison duration, images reconstructed 1.5 Patients intravenously administered 0.5...
BackgroundHigh-risk muscle-invasive bladder cancer (MIBC) has a poor prognosis. Old trials showed that external beam radiotherapy (EBRT) after radical cystectomy (RC) decreases the incidence of local recurrences but induces severe toxicity.ObjectiveTo evaluate toxicity and control rate adjuvant EBRT RC delivered with volumetric arc radiotherapy.Design, setting, participantsThis is multicentric phase 2 trial. From August 2014 till October 2020, we treated 72 high-risk MIBC patients RC....
Abstract Background The outcome of patients with muscle-invasive bladder cancer (MIBC) remains poor, despite aggressive treatments. Inadequate primary staging, classically performed by computed tomography (CT)-imaging, could lead to inappropriate treatment and might contribute these poor results. Although not (yet) adapted international guidelines, several reports have indicated the superiority 18 F-fluorodeoxyglucose-positron emission tomography-CT ( F-FDG-PET-CT) compared CT in detection...
5025 Background: Prospective reports suggest metastasis directed therapy (MDT) in oligometastatic castration sensitive prostate cancer (omCSPC) is associated with improved treatment outcomes. Here we present long term outcomes of the phase II STOMP and ORIOLE trials assess ability a high-risk (HiRi) mutational signature to provide prognostic predictive information regarding MDT response. Methods: Patients omCSPC (< 3 lesions) enrolled on (n = 62) 54) randomized or observation were pooled....